Luoxin Pharmaceuticals Group Stock Co., Ltd. (002793.SZ)
CNY 4.21
(-0.94%)
CNY 4.21
(-0.94%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 2.34 Billion | 3.58 Billion | 6.47 Billion | 6.09 Billion | 7.58 Billion | 935.44 Million |
| Cost of Revenue | 1.37 Billion | 2.62 Billion | 3.22 Billion | 2.82 Billion | 2.79 Billion | 692.62 Million |
| Gross Profit | 964.58 Million | 959.33 Million | 3.25 Billion | 3.26 Billion | 4.78 Billion | 242.82 Million |
| Operating Expenses | 1.61 Billion | 2.37 Billion | 2.56 Billion | 2.71 Billion | 3.98 Billion | 114.44 Million |
| Selling, General and Administrative Expenses | 1.31 Billion | 1.85 Billion | 1.96 Billion | 2.1 Billion | 3.34 Billion | 39.24 Million |
| Research and Development Expenses | 112.26 Million | 204.72 Million | 320.94 Million | 361.26 Million | 419.99 Million | 33.35 Million |
| Other Expenses | 105.64 Million | 312.72 Million | 285.59 Million | 252.24 Million | 220.71 Million | -241.67 Thousand |
| Cost and Expenses | 2.95 Billion | 5 Billion | 5.79 Billion | 5.54 Billion | 6.78 Billion | 807.06 Million |
| Operating Income | -490.15 Million | -1.41 Billion | 698.95 Million | 425.73 Million | 725.06 Million | 127.7 Million |
| Interest Expense | 75.97 Million | 122.67 Million | 105.18 Million | 50.36 Million | 46.82 Million | 4.13 Million |
| Income Tax Expense | 164.8 Million | -204.95 Million | 63.55 Million | 66.33 Million | 70.45 Million | 16.11 Million |
| Earnings before Tax | -619.96 Million | -1.46 Billion | 485.2 Million | 408.93 Million | 724.21 Million | 127.46 Million |
| Net Income | -661.13 Million | -1.25 Billion | 406.09 Million | 320.7 Million | 633.95 Million | 111.34 Million |
| Earnings Per Share Basic | -0.61 | -0.88 | 0.28 | 0.22 | 1.76 | 0.10 |
| Earnings Per Share Diluted | -0.61 | -0.88 | 0.28 | 0.22 | 0.57 | 0.10 |
| Weighted Average Shares Outstanding | 1.08 Billion | 1.42 Billion | 1.45 Billion | 1.45 Billion | 359.7 Million | 1.06 Billion |
| Weighted Average Shares Outstanding (Diluted) | 1.08 Billion | 1.42 Billion | 1.45 Billion | 1.45 Billion | 359.7 Million | 1.06 Billion |
| Gross Margin | 0.41 | 0.27 | 0.50 | 0.54 | 0.63 | 0.26 |
| EBIT Margin | -0.14 | -0.28 | 0.14 | 0.12 | 0.13 | 0.18 |
| Profit Margin | -0.28 | -0.35 | 0.06 | 0.05 | 0.08 | 0.12 |
| EBITDA | -320.08 Million | -1.06 Billion | 790.16 Million | 642.69 Million | 942.36 Million | 723.42 Million |
| Earnings Before Tax Margin | -0.21 | -0.39 | 0.11 | 0.07 | 0.10 | 0.14 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 617.57 Million | 570.5 Million | 683.69 Million | 530.27 Million | 2.34 Billion | 571.05 Million |
| Cost of Revenue | 322.79 Million | 316.69 Million | 436.3 Million | 334.11 Million | 1.37 Billion | 305.24 Million |
| Gross Profit | 294.78 Million | 253.81 Million | 247.39 Million | 196.16 Million | 964.58 Million | 265.81 Million |
| Operating Expenses | 459.79 Million | 306.62 Million | 284.08 Million | 528.19 Million | 1.45 Billion | 313.16 Million |
| Selling, General and Administrative Expenses | 418.08 Million | 202.08 Million | 266.67 Million | 423.79 Million | - | 406.03 Million |
| Research and Development Expenses | 19.14 Million | 14.7 Million | 15.34 Million | 10.81 Million | - | 29.28 Million |
| Other Expenses | -22.55 Million | 8.63 Million | -2.05 Million | -93.58 Million | -57.75 Million | 3.21 Million |
| Cost and Expenses | 782.58 Million | 623.31 Million | 720.38 Million | 862.3 Million | 2.83 Billion | 618.4 Million |
| Operating Income | -165.01 Million | -73.81 Million | -36.69 Million | -332.03 Million | -490.15 Million | -102.19 Million |
| Interest Expense | 16.42 Million | 15.92 Million | 14.85 Million | 13.75 Million | 75.97 Million | 15.36 Million |
| Income Tax Expense | 15.15 Million | 6.58 Million | 4.53 Million | 123.43 Million | 164.8 Million | 25.9 Million |
| Earnings before Tax | -175.22 Million | -65.18 Million | -42.9 Million | -374.75 Million | -619.96 Million | -98.98 Million |
| Net Income | -176.66 Million | -52.04 Million | -36.66 Million | -431.62 Million | -661.13 Million | -102.62 Million |
| Earnings Per Share Basic | -0.17 | -0.05 | -0.03 | -0.40 | - | -0.09 |
| Earnings Per Share Diluted | -0.17 | -0.05 | -0.03 | -0.40 | - | -0.09 |
| Weighted Average Shares Outstanding | 1.06 Billion | 1.06 Billion | 1.06 Billion | 1.08 Billion | 1.08 Billion | 1.08 Billion |
| Weighted Average Shares Outstanding (Diluted) | 1.06 Billion | 1.06 Billion | 1.06 Billion | 1.08 Billion | 1.08 Billion | 1.08 Billion |
| Gross Margin | 0.48 | 0.44 | 0.36 | 0.37 | 0.41 | 0.47 |
| EBIT Margin | -0.26 | -0.08 | -0.04 | -0.53 | - | -0.06 |
| Profit Margin | -0.29 | -0.09 | -0.05 | -0.81 | -0.28 | -0.18 |
| EBITDA | -158.79 Million | -47.63 Million | -29.07 Million | -280.11 Million | - | -37.11 Million |
| Earnings Before Tax Margin | -0.27 | -0.13 | -0.05 | -0.63 | -0.21 | -0.18 |
8410
RMBL
BBDC4
VAN
VBIND
0309